Medically reviewed on Feb 24, 2019
(a DAP a leen)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Differin: 0.1% (45 g)
Generic: 0.1% (45 g)
Differin: 0.1% (45 g); 0.3% (45 g) [contains edetate disodium, methylparaben, propylene glycol]
Differin: 0.1% (15 g, 45 g) [fragrance free, oil free; contains edetate disodium, methylparaben, propylene glycol]
Generic: 0.1% (45 g); 0.3% (45 g)
Differin: 0.1% (59 mL) [contains methylparaben, propylene glycol, propylparaben]
Generic: 0.1% (59 mL)
Plixda: 0.1% (30 ea) [contains alcohol, usp]
Generic: 0.1% (60 mL)
Brand Names: U.S.
- Differin [OTC]
- Acne Products
- Topical Skin Product, Acne
Retinoid-like compound which is a modulator of cellular differentiation, keratinization, and inflammatory processes, all of which represent important features in the pathology of acne vulgaris
Topical: Minimal; only trace amounts have been measured in serum after chronic application
Onset of Action
8 to 12 weeks
Terminal: 7 to 51 hours (gel)
Use: Labeled Indications
Acne vulgaris: Treatment of acne vulgaris.
Off Label Uses
Topical adapalene for the management of rosacea has been studied in a limited number of patients, with data suggesting it may be a useful alternative to topical metronidazole. An international consensus statement on the treatment of rosacea recognizes that evidence is limited to support the use of topical retinoids, which may aggravate underlying vascular disease and have irritant properties, but that some retinoids such as adapalene may be more tolerable. Data from larger, controlled trials are needed to establish adapalene's role in the management of rosacea.
Hypersensitivity to adapalene or any component of the formulation.
Lotion: There are no contraindications listed in the manufacturer's labeling.
OTC labeling: When used for self-medication, do not use on damaged skin (cuts, abrasions, eczema, sunburn).
Documentation of allergenic cross-reactivity for retinoids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Canadian labeling: Additional contraindications (not in US labeling): Patients with eczema or seborrheic dermatitis; women who are pregnant or planning to become pregnant.
Acne vulgaris: Topical: Apply once daily in the evening before bedtime. If irritation occurs, may reduce the frequency of application.
Rosacea (off-label use): Topical: 0.1% Gel: Apply to affected area once daily in the evening for up to 12 weeks (Altinyazar 2005)
Refer to adult dosing.
Acne vulgaris, treatment: Children ≥7 years and Adolescents: Limited data available in ages <12 years (Eichenfield 2013): Topical: Apply once daily; cream, gel, or solution should be applied in the evening (at bedtime). Note: During the initial 2 weeks of therapy, it may appear that acne worsens; full effect may take up to 8 to 12 weeks of therapy.
For topical use only; not for oral, ophthalmic, or intravaginal use. Avoid contact with abraded, broken, eczematous, or sunburned skin, mucous membranes, eyes, lips, and angles of the nose. Moisturizers may be used if necessary; avoid alpha hydroxy or glycolic acid-containing products. A mild transitory sensation of warmth or slight stinging may occur shortly after application.
Cream/gel: Apply a thin film to clean/dry skin in the evening before bedtime; apply enough to cover entire affected area.
External pad: Remove pad from foil just prior to use. Before bedtime, wash and dry area to be treated, then apply pad containing topical solution to affected areas. Discard pad after single use.
Lotion: Apply after washing gently with a mild or soapless cleanser and then pat dry; dispense a nickel size amount (3 to 4 pump actuations) to cover entire face.
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not freeze. Protect from light.
Lotion: Protect from light and heat; do not refrigerate.
Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Avoid combination
Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Monitor therapy
Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives. Avoid combination
Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives. Avoid combination
Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives. Avoid combination
Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Monitor therapy
Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Monitor therapy
>10%: Dermatologic: Xeroderma (≤45%), exfoliation of skin (≤44%), erythema (≤38%), burning sensation of skin (≤29%), stinging of the skin (≤29%)
1% to 10%: Dermatologic: Skin abnormalities (1% to 6%; discomfort), desquamation (2%), pruritus (≤2%), skin irritation (1% to 2%), sunburn (1% to 2%)
≤1%, postmarketing, and/or case reports: Acne flare, angioedema (gel), application site pain (gel), conjunctivitis, contact dermatitis, dermatitis, eczema, eyelid edema, facial edema (gel), skin discoloration, skin rash (cream/gel), swelling of lips (gel)
Concerns related to adverse effects:
• Hypersensitivity reactions: Reactions such as pruritus, face edema, eyelid edema, and swelling have been reported. Discontinue use immediately if allergic or anaphylactoid/anaphylactic reactions occur.
• Photosensitivity: Use is associated with increased susceptibility/sensitivity to UV light; avoid sunlamps or excessive sunlight exposure. Daily sunscreen use and other protective measures are recommended. Patients with sunburn should discontinue use until sunburn has healed.
• Skin irritation: Certain cutaneous signs and symptoms such as erythema, dryness, scaling, stinging/burning, or pruritus may occur during treatment; these are most likely to occur during the first 2 to 4 weeks and will usually lessen with continued use. Treatment can increase skin sensitivity to weather extremes of wind or cold. Concomitant topical medications (eg, medicated or abrasive soaps and cleansers, or cosmetics with a strong drying effect, products with high concentrations of alcohol, astringents, spices or limes) should be avoided due to increased skin irritation. Depending on the severity of irritation, use moisturizer, reduce the frequency of application, or discontinue use.
• Appropriate use: For external use only; avoid contact with abraded, broken, eczematous, or sunburned skin, mucous membranes, eyes, lips, and angles of the nose. Wax depilation is not recommended.
Pregnancy Risk Factor
Adverse effects were observed in animal reproduction studies. Retinoids may cause harm when administered during pregnancy. A case report described maternal use of adapalene 1 month prior to pregnancy and through 13 weeks' gestation; cerebral and ocular malformations were reported in the exposed fetus which resulted in termination of pregnancy (Autret 1997). In clinical trials, women of childbearing potential were required to have a negative pregnancy test prior to therapy.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience redness, dry skin, scaling, or burning. Have patient report immediately to prescriber severe skin irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about adapalene topical
- Adapalene topical Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 346 Reviews
- Drug class: topical acne agents
- Adapalene (AHFS Monograph)
- Adapalene (FDA)
- Adapalene Cream (FDA)
- Adapalene Lotion (FDA)
- Adapalene Solution (FDA)
Other brands: Differin